For instance, mismatch-repair status (DNA repair and replication gene mutations such as POLD1, POLE and MSH2) could predict clinical benefit of Pembrolizumab for colon cancer patients and the high somatic mutation burden was associated with prolonged PFS survival [16]. This evidence concerns the gene MSH2 and malignant colon neoplasm.